On January 10, 2022 Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, reported a corporate update and announced anticipated milestones for 2022 (Press release, Kiniksa Pharmaceuticals, JAN 10, 2022, View Source [SID1234598480]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"2021 was a transformational year for Kiniksa. We progressed to a commercial-stage company with the successful launch of ARCALYST for the treatment of recurrent pericarditis. We are pleased with the strong physician and patient adoption and expect to provide annual guidance along with fourth quarter and full-year 2021 financial results," said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. "This year, we look forward to continued commercial excellence with ARCALYST, as well as reporting data from the Phase 2b trial of vixarelimab in prurigo nodularis, and conducting the Phase 2 trial of KPL-404 in rheumatoid arthritis."

Corporate Update

Kiniksa’s resources are currently focused on growing the ARCALYST franchise and progressing the clinical trials of vixarelimab in prurigo nodularis and KPL-404 in rheumatoid arthritis.
Kiniksa’s year-end 2021 cash, cash equivalents and short-term investments of approximately $182 million (unaudited) are expected to fund its current operating plan into 2024.
Portfolio Update
ARCALYST (IL-1α and IL-1β cytokine trap)

Kiniksa expects to provide full-year 2022 ARCALYST net revenue guidance with its fourth quarter and full-year 2021 financial results.
Mavrilimumab (monoclonal antibody inhibitor targeting GM-CSFRα)

As previously reported, the Phase 3 portion of the Phase 2/3 trial of mavrilimumab in COVID-19-related acute respiratory distress syndrome (ARDS) did not meet its primary efficacy endpoint of the proportion of patients alive and free of mechanical ventilation at Day 29.
Kiniksa continues to believe in the potential broad utility of mavrilimumab and is evaluating next steps for the molecule.
Vixarelimab (monoclonal antibody inhibitor of signaling through OSMRβ)

Kiniksa expects data from the Phase 2b dose-ranging clinical trial of once-monthly subcutaneous vixarelimab in prurigo nodularis in the second half of 2022.
KPL-404 (monoclonal antibody inhibitor of CD40-CD154 signaling)

Kiniksa is enrolling and dosing patients in a Phase 2 clinical trial of KPL-404 in rheumatoid arthritis which is designed to enable potential development in a spectrum of autoimmune diseases believed to be mediated by the CD40-CD154 pathway.
40th Annual J.P. Morgan Healthcare Conference
Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa will provide a corporate presentation at the 40th Annual J.P. Morgan Healthcare Conference today, Monday, January 10, 2022, at 1:30 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.